New schizophrenia drug passes early safety check in small study

NCT ID NCT04506905

Completed Symptom relief Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called MK-8189 (elpipodect) in 63 people with schizophrenia, including both younger and older adults, as well as healthy older volunteers. The main goal was to check the drug's safety and how the body processes it, not to cure the disease. Results will help decide if larger studies should move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Collaborative NeuroScience Network ( Site 0008)

Long Beach, California, 90806, United States
Hassman Research Institute ( Site 0007)

Berlin, New Jersey, 08009, United States
Parexel ( Site 0004)

Glendale, California, 91206, United States
RCA at Fort Lauderdale Behavioral Health Center ( Site 0006)

Oakland Park, Florida, 33334, United States
Velocity Clinical Research, Hallandale Beach ( Site 0001)

Hallandale, Florida, 33009, United States
Woodland Research Northwest, LLC ( Site 0002)

Rogers, Arkansas, 72758-6442, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.